Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.

Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."

What is Atrial Fibrillation (A-Fib)?

"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.

The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.

"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.

The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.

Tips for Quitting Smoking

Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:

1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.

2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.

3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.

4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.

5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.

6. Drinking water can help flush nicotine out of your system faster, reducing cravings.

7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.

Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.

The launch of the weight-loss drug Wegovy has sparked fresh concerns among pharmacists in the UK, who warn that the new tablet format could make it easier for manufacturers to produce and sell counterfeit medicines.

Wegovy Demand Sparks Counterfeit Concern

The once-daily semaglutide pill, developed by Novo Nordisk, recently became available through private high street and online pharmacies after receiving approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

While the pill is expected to help patients who are reluctant to use injections, experts fear it may also increase the risk of a growing black market for fake weight-loss drugs.

According to a survey conducted by the National Pharmacy Association (NPA) with 310 pharmacies, 97% believe that the weight loss tablet could lead to an increase in counterfeit products being sold unlawfully.

Olivier Picard, chairman of the National Pharmacy Association said, “As this survey shows, pharmacies are concerned about a dangerous and growing black market for weight loss medicines, with tablet form of medication likely to be easier for criminals to counterfeit.”

He said that all patients must visit an authorised pharmacy for Wegovy pills.

He added: “Patients should only ever obtain weight loss medication from a regulated pharmacy after an appropriate consultation with a healthcare professional. Fake medicines pose a serious risk to health because they may contain harmful ingredients or incorrect doses.”

Also read: Wegovy Weight Loss Pill Available in UK Pharmacies From Today: All You Should Know

Global Concern

Unlike injectable medications of GLP-1, tablets often require less sophisticated manufacturing equipment, which makes it easier to make counterfeits.

As the medicated weight loss market is rising after the popularity of GLP-1 medications increased, criminals can produce fake pills on a large scale, using simple equipment.

Counterfeit GLP-1 medicines have already become a growing global concern. In September 2025, the European Medicines Agency (EMA) said that there had been a sharp rise in illegal forms of semaglutide and other GLP-1 medicines online.

The agency also warned that these fake medicines may contain no active ingredient, improper doses, or harmful substances that can lead to failure of treatment or serious health complications.

Demand for GLP-1 medicines such as Wegovy and Mounjaro has soared worldwide as studies continue to demonstrate significant weight loss benefits.

Also read: Can Ozempic-Like GLP-1 Drugs Slow Aging, Boost Longevity?

Clinical trials of the oral Wegovy tablet have shown participants taking the highest dose lost approximately 14% to 17% of their body weight over 64 weeks when combined with diet and exercise. However, pharmacists say the popularity of these treatments has also created opportunities for fraudsters.

Experts urge consumers to avoid purchasing weight-loss medicines from unofficial online sellers or social media advertisements, regardless of how attractive the prices appear.

Genuine GLP-1 medicines require a medical consultation and prescription, and authorised pharmacies carry out necessary clinical checks before selling them.

About Wegovy

The semaglutide (Wegovy) tablet is the first oral glucagon-like peptide-1 (GLP-1) medicine approved in the UK for weight loss.

It can be prescribed alongside a reduced-calorie diet and increased physical activity for adults who have obesity (BMI of 30 or above), or are overweight (BMI between 27 and 30), and have at least one weight-related comorbidity

The United States Department of Health and Human Services (HHS) has announced more than $281 million in funding opportunities through 15 grant programs aimed at addressing addiction, deaths from overdose, mental illness and strengthening recovery services across the country.

HHS Announces $281 Million To Address Addiction & Recovery

The funding, announced by the Substance Abuse and Mental Health Services Administration (SAMHSA), is supposed to support several health initiatives, including substance use and its treatment, suicide prevention, trauma-informed care, overdose, integrated behavioral healthcare, workforce development, recovery support services, and training for first responders.

Part Of Trump’s Great American Recovery Initiative

The investment forms part of the Trump administration's Great American Recovery Initiative, which seeks to expand healthcare in the midst of the nation's ongoing addiction and mental health crises.

Announcing the initiative, HHS Secretary Robert F. Kennedy Jr. said the funding would help communities get access to treatment, strengthen and improve recovery services, prevent overdoses, and provide frontline workers with the resources needed to save lives.

“We are investing more than $281 million through 15 grant programs to expand treatment, strengthen recovery services, prevent overdose, and equip communities with the tools they need to save lives, restore families, and Make America Healthy Again,” Kennedy said.

SAMHSA Principal Deputy Assistant Secretary Christopher D. Carroll said the grants reflect the agency's commitment to addressing the prevention of addiction and overdose-related deaths and treatment of long-term recovery support. The announcement comes amid continued efforts by the federal government to increase investments in behavioral health.

The grants will support effective treatment, strengthen prevention efforts, expand recovery services, and provide resources for the professionals and organizations working on the front lines of the addiction and mental health crisis,” Carroll said.

Read more: 80 Years Of CDC: How America’s Premiere Health Institution Changed Under Donald Trump’s Administration

Other Behavioural Healthcare Initiatives

Last month, HHS allocated more than $700 million in additional funding opportunities, including support for the 988 Suicide & Crisis Lifeline, Certified Community Behavioral Health Clinics (CCBHCs), homelessness initiatives, and the new STREETS program, which aims to reach enable homeless people get treatment and recovery services.

Earlier this year, SAMHSA also distributed nearly $800 million in block grants to states and territories to strengthen mental health services and substance use prevention, treatment, and recovery programs, highlighting federal efforts to expand behavioral health infrastructure.

Despite these investments, the administration's handling of behavioral health funding has faced scrutiny. In January, the Trump administration briefly canceled nearly $2 billion in addiction and mental health grants before reversing the decision following widespread criticism from lawmakers, public health experts and service providers, who warned that disruptions could jeopardize essential treatment and recovery programs.

The latest funding announcement also comes as the United States continues to grapple with high rates of mental illness and substance use disorders.

SAMHSA says that more than 21 million American adults were grappling with both a mental illness and a substance use disorder in 2024, underscoring the need for integrated treatment and recovery services.

For Canadians living with severe mental illnesses, the latest delay in making mental disorders eligible for Medical Assistance in Dying (MAID) has reignited feelings of despair. People who had hoped the law would eventually recognize unbearable psychological suffering say they now feel abandoned by a system that has repeatedly postponed the change.

Impact Of Canada’s Latest MAID Decision

Many patients told the media that after years of exhausting treatment options, the repeated delay in making mental illness eligible for MAID has left them feeling as though they have “nothing” left to hope for.

One woman, Ann, who has lived with severe mental illness for decades, told CTV News she has tried virtually every available treatment, including medications, psychotherapy, electroconvulsive therapy (ECT) and ketamine therapy, but nothing has eased her suffering.

She said the repeated delays have left her feeling “absolutely abandoned,” adding, “They've left me with nothing.”

Another patient, Nicole, said she has struggled with debilitating psychiatric illness for years despite receiving extensive treatment.

She told the media that knowing MAID might one day become available had given her a sense of comfort, even if she never ultimately chose it. With the expansion postponed again, she says that reassurance has disappeared.

Read more: Men Account For Nearly 3 Out Of 4 Suicides In India — Are We Ignoring A Growing Men's Mental Health Crisis?

Why Has Canada Delayed Making Mental Illness Eligible For MAID?

Canada currently allows MAID for eligible adults experiencing irremediable, incurable and untreatable physical illnesses under a strict legal framework. However, people with severe mental illness who are struggling to get better still remain ineligible.

The federal government has delayed the expansion several times, with eligibility now expected no earlier than March 2027.

More recently, a parliamentary committee recommended indefinitely excluding mental illness as the sole qualifying condition, arguing that Canada is not yet equipped to implement the policy safely and fairly.

Supporters of expanding MAID say the current law unfairly discriminates between physical and psychological suffering. They argue that some people with severe psychiatric disorders endure decades of relentless symptoms despite exhausting every treatment option available.

Critics, however, say determining whether a mental illness is truly “irremediable” remains far more difficult than for many physical illnesses. Experts also warn that physicians currently lack reliable tools to distinguish a sustained request for MAID from suicidal thinking that may improve with treatment.

Mental health specialists have also emphasized that gaps in access to psychiatric care, housing, and social support must be addressed before eligibility is broadened.

The Centre for Addiction and Mental Health (CAMH) has argued that while psychological suffering can be just as profound as physical suffering, more evidence and safeguards are needed before extending MAID to mental illness alone.

MAID Accounts For About 5% of Deaths in Canada

According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.

The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".

As one of Canada's most controversial healthcare policies continues to be debated, people like Ann and Nicole say they remain caught in limbo, waiting for a decision that could change the choices available to those living with severe, enduring mental illness.